348 related articles for article (PubMed ID: 27678453)
21. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
22. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
23. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
[TBL] [Abstract][Full Text] [Related]
24. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Heller G; McCormack R; Kheoh T; Molina A; Smith MR; Dreicer R; Saad F; de Wit R; Aftab DT; Hirmand M; Limon A; Fizazi K; Fleisher M; de Bono JS; Scher HI
J Clin Oncol; 2018 Feb; 36(6):572-580. PubMed ID: 29272162
[TBL] [Abstract][Full Text] [Related]
25. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI
Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088
[TBL] [Abstract][Full Text] [Related]
26. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
Gu T; Li J; Chen T; Zhu Q; Ding J
Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
30. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
32. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer.
Onstenk W; de Klaver W; de Wit R; Lolkema M; Foekens J; Sleijfer S
Cancer Treat Rev; 2016 May; 46():42-50. PubMed ID: 27107266
[TBL] [Abstract][Full Text] [Related]
33. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
35. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
[TBL] [Abstract][Full Text] [Related]
36. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
38. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
[TBL] [Abstract][Full Text] [Related]
39. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ
Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758
[TBL] [Abstract][Full Text] [Related]
40. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]